StreetInsider.com News Articles

Gyre Therapeutics to Participate in Upcoming September Investor Conferences

Thu, 03 Sep 2026 07:00:00 -0400

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that Company management will participate in the Cantor Global Healthcare Conference and the Morgan Stanley Healthcare Conference, both being held this month in New York, NY. Information about both conferences is below:

Cantor Global Healthcare Conference
Date: Wednesday, September 9, 2026
Time: 9:45 a.m. ET
Format: Fireside chat

Morgan Stanley Healthcare Conference
Date: Wednesday, September 16, 2026
Time: 1:05

Gyre Therapeutics to Participate in Upcoming September Investor Conferences

Thu, 03 Sep 2026 07:00:00 -0400

Cantor Global Healthcare Conference
Date: Wednesday, September 9, 2026
Time: 9:45 a.m. ET
Format: Fireside chat

Morgan Stanley Healthcare Conference
Date: Wednesday, September 16, 2026
Time: 1:05

Form 8-K GYRE THERAPEUTICS, INC. For: Aug 26

Wed, 26 Aug 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260826/26978140.html

Form 8-K GYRE THERAPEUTICS, INC. For: Aug 26

Wed, 26 Aug 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260826/26978140.html

Form 10-Q GYRE THERAPEUTICS, INC. For: Jun 30

Fri, 07 Aug 2026 17:01:00 -0400

http://archive.fast-edgar.com/20260807/AJ2Z422FZZ2RU9Z2229G2ZYNAB9RZZ223I82

Filed on: August 7, 2026

Form 10-Q GYRE THERAPEUTICS, INC. For: Jun 30

Fri, 07 Aug 2026 17:01:00 -0400

http://archive.fast-edgar.com/20260807/AJ2Z422FZZ2RU9Z2229G2ZYNAB9RZZ223I82

Filed on: August 7, 2026

Form 8-K GYRE THERAPEUTICS, INC. For: Aug 07

Fri, 07 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260807/26887739.html

Form 8-K GYRE THERAPEUTICS, INC. For: Aug 07

Fri, 07 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260807/26887739.html

Gyre Therapeutics (GYRE) Misses Q2 EPS by 6c

Fri, 07 Aug 2026 07:36:06 -0400

Gyre Therapeutics (NASDAQ: GYRE) reported Q2 EPS of ($0.12), $0.06 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $29.1 million versus the consensus estimate of $26.49 million.

For earnings history and earnings-related data on Gyre Therapeutics (GYRE) click here.

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

Fri, 07 Aug 2026 07:00:00 -0400

Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12)

Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed

NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China’s CDE in May 2026

SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced financial results for the second quarter ended June 30, 2026, and provided a business update.

Dr. Ying Luo, President

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

Fri, 07 Aug 2026 07:00:00 -0400

Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12)

Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed

NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China’s CDE in May 2026

Dr. Ying Luo, President

Form 4 GYRE THERAPEUTICS, INC. For: Aug 03 Filed by: Weston Claire

Tue, 04 Aug 2026 20:46:00 -0400

si-local-file:///var/storage/secattach/20260804/26868601.html

Form 4 GYRE THERAPEUTICS, INC. For: Aug 03 Filed by: Weston Claire

Tue, 04 Aug 2026 20:46:00 -0400

si-local-file:///var/storage/secattach/20260804/26868601.html

Form 4 GYRE THERAPEUTICS, INC. For: Aug 03 Filed by: Kirkby Maxwell

Tue, 04 Aug 2026 20:40:00 -0400

si-local-file:///var/storage/secattach/20260804/26868592.html

Form 4 GYRE THERAPEUTICS, INC. For: Aug 03 Filed by: Kirkby Maxwell

Tue, 04 Aug 2026 20:40:00 -0400

si-local-file:///var/storage/secattach/20260804/26868592.html

Form 3 GYRE THERAPEUTICS, INC. For: Aug 01 Filed by: Weston Claire

Tue, 04 Aug 2026 20:31:00 -0400

si-local-file:///var/storage/secattach/20260804/26868580.html

Form 3 GYRE THERAPEUTICS, INC. For: Aug 01 Filed by: Weston Claire

Tue, 04 Aug 2026 20:31:00 -0400

si-local-file:///var/storage/secattach/20260804/26868580.html

Form 3 GYRE THERAPEUTICS, INC. For: Aug 01 Filed by: Kirkby Maxwell

Tue, 04 Aug 2026 20:24:00 -0400

si-local-file:///var/storage/secattach/20260804/26868569.html

Form 3 GYRE THERAPEUTICS, INC. For: Aug 01 Filed by: Kirkby Maxwell

Tue, 04 Aug 2026 20:24:00 -0400

si-local-file:///var/storage/secattach/20260804/26868569.html

Form EFFECT GYRE THERAPEUTICS, INC.

Tue, 04 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260804/26860780.html

Form EFFECT GYRE THERAPEUTICS, INC.

Tue, 04 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260804/26860780.html

Form 8-K GYRE THERAPEUTICS, INC. For: Jul 10

Thu, 16 Jul 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260716/26780150.html

Form 8-K GYRE THERAPEUTICS, INC. For: Jul 10

Thu, 16 Jul 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260716/26780150.html

Gyre Therapeutics adds three directors to its board

Thu, 16 Jul 2026 16:05:13 -0400

Gyre Therapeutics, Inc. (Nasdaq: GYRE) announced the appointment of three new members to its board of directors, effective August 1, 2026, according to a press release.

The new directors are Yue Xiong, Ph.D., the company's Chief Scientific Officer; Maxwell Kirkby; and Claire Weston, Ph.D.

Dr. Xiong will serve as a Class I director with a term expiring at the 2028 annual stockholder meeting. He has served as Gyre's Chief Scientific Officer since May 2026 and previously held the same role at Cullgen, Inc. before its merger with Gyre. He is a former professor at the University of North Carolina at Chapel Hill

Gyre Therapeutics Appoints Three New Members to its Board of Directors

Thu, 16 Jul 2026 16:05:00 -0400

SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that its Board of Directors has appointed three new members, effective August 1, 2026: Yue Xiong, Ph.D., the Company's Chief Scientific Officer; Maxwell (“Max”) Kirkby; and Claire Weston, Ph.D. With these appointments, the Board expands its scientific, clinical development, and cross-border biopharmaceutical operating expertise as Gyre advances its broad pipeline of products targeting numerous therapeutic areas including fibrosis, cancer, inflammation and pain.

Dr.